Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Cognetivity Neurosciences's Gross Margin % or its related term are showing as below:
CGNSF's Gross Margin % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 40.25 * Ranked among companies with meaningful Gross Margin % only.
Cognetivity Neurosciences had a gross margin of N/A% for the quarter that ended in Oct. 2023 => No sustainable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cognetivity Neurosciences had a gross margin of N/A% for the quarter that ended in Oct. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cognetivity Neurosciences Gross Margin % Related Terms
Cognetivity Neurosciences Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGNSF vs VEEV, GEHC, HQY: Gross Margin % Comparison
For the Health Information Services subindustry, Cognetivity Neurosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognetivity Neurosciences Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cognetivity Neurosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cognetivity Neurosciences (CGNSF) has a Gross Margin % of 0.00% as of Oct. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on Cognetivity Neurosciences and its competitors.
Is Cognetivity Neurosciences' Gross Margin % too high?
Cognetivity Neurosciences' current Gross Margin % is 0.00%.
How does Cognetivity Neurosciences' Gross Margin % compare to VEEV and GEHC?
Cognetivity Neurosciences' Gross Margin % of 0.00% can be compared against companies in the Healthcare Providers & Services industry. The industry median Gross Margin % is 40.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.25, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cognetivity Neurosciences and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cognetivity Neurosciences's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (CGNSF) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cognetivity Neurosciences (CGNSF), the current Gross Margin % is 0.00% as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGNSF has been successfully added to your 
